GDTC
CytoMed TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The best constructive read is that the March 31, 2026 company update did provide tangible operating hooks: ANGELICA had treated six patients, dose escalation was moving forward, management still targeted Phase I completion in 2026, and a Malaysia IND submission was targeted before June 2026. With an equity value around the low teens of millions, even modest clinical or regulatory confirmation could move the stock disproportionately.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Cash and bank balances fell to US$1.63 million at December 31, 2025 from US$3.87 million a year earlier, elevating near-term financing and runway risk.
Momentum
64
Value
41
Sentiment
38
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.95 · Bull $1.35 · Bear $0.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-16 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Why
Momentum64 · Δ7d -
Value41 · Δ7d -0.1
Sentiment38 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
64
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
38
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 64.3 / Value 41.1 / Sentiment 37.6
Fundamentals (TTM)As of 2026-07-16
Fundamentals (TTM)
As of 2026-07-16
Market Cap
$12.07M
Beta
-
Shares Out
11.83M
P/E (TTM) · Derived
-3.9
P/S (TTM)
90.31
P/FCF (TTM) · Derived
-3.66
Rev YoY
-
EPS YoY
-106.1%
Gross Margin
-278.4%
Op Margin
-1632.3%
Net Debt
-$1.25M
Current Ratio
5.17
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology